Updated:
Pharmaceutical Product Development
Pharmaceutical Product Development is a corporate investor based in Wilmington, US. It manages approximately $7 billion in assets across four funds, primarily...
Pharmaceutical Product Development
Pharmaceutical Product Development is a corporate investor based in Wilmington, US. It manages approximately $7 billion in assets across four funds, primarily focused on North America.
General information
Firm type
Corporate Investor
Year founded
1985
Location
Region
North America
Country
United States
City
Wilmington
Corporate office
929 North Front Street, Wilmington, NC, United States
Additional offices
Middleton, WI · Richmond, VA · Waltham, MA
Principals
Fred Eshelman
Founder
Sector focus
Frequently asked questions
Who runs investment decisions at PPD?
PPD is no longer an independent investment entity. It was acquired by Thermo Fisher Scientific in December 2021. Investment and capital-allocation decisions now flow through Thermo Fisher's corporate structure. Prior to the acquisition, the firm's private-equity owners — principally The Carlyle Group and Hellman & Friedman — directed its financial strategy.
How did The Carlyle Group and Hellman & Friedman exit their PPD positions?
Both firms sold their stakes through the 2021 sale to Thermo Fisher Scientific for $17.4 billion. Abu Dhabi Investment Authority and GIC Private Limited had joined the 2017 recapitalization and exited as part of the same transaction.
What is PPD's known posture on co-investments alongside external GPs?
During the period of private-equity ownership, PPD's recapitalizations involved co-investors such as ADIA and GIC alongside the lead sponsors. Those structures were oriented toward acquiring the operating company, not toward co-investing in portfolio companies. Since December 2021, PPD has functioned as a wholly owned subsidiary of Thermo Fisher Scientific.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: